Issue #22 | May 14, 2026 | The PFA Arms Race Hits HRS
Three catheter ablation studies dropped at HRS 2026 in under 72 hours. Medtronic presented pivotal data for its Sphere-9 catheter in ventricular tachycardia—a different target than the atrial fibrillation fight everyone else is waging. Abbott’s TactiFlex Duo, the first dual-energy catheter combining pulsed-field and radiofrequency ablation, posted 87% arrhythmia-free outcomes at six months in the FlexPulse IDE trial. And Boston Scientific fired back with FARAFLEX data showing 95.5% pulmonary vein isolation durability at two months, defending a PFA franchise that lost significant market share over the past two quarters. Three companies, three distinct strategies, one conference. Welcome to Issue #22.
Medtronic presented pivotal data from the STOP-VT IDE trial at Heart Rhythm Society 2026 in San Francisco, showing its Sphere-9 pulsed-field ablation catheter achieved 65.5% freedom from ventricular tachycardia recurrence at six months in patients with structural heart disease. The Sphere-9 is a lattice-tipped catheter designed specifically for VT ablation—a substrate mapping and ablation approach that differs fundamentally from the PFA-for-AF paradigm that dominates the conference. Medtronic has submitted the data to FDA as part of its breakthrough device pathway designation. (Source: Medtronic, HRS 2026, May 12–14)
VT ablation in structural heart disease has historically been one of the most challenging procedures in electrophysiology. Legacy RF-only ablation catheters achieve VT-free rates that vary widely depending on substrate complexity, and recurrence rates at one year remain high. The Sphere-9’s lattice design creates larger, more uniform lesions than point-by-point RF catheters—critical in VT ablation where the arrhythmia circuit often runs through scarred, thick ventricular tissue that standard catheters struggle to reach.
Why It Matters: Medtronic is not competing in the AF ablation market with Sphere-9. It is targeting VT—a clinically harder problem with fewer existing solutions and higher unmet need. If the FDA grants clearance through the breakthrough pathway, Sphere-9 becomes the first PFA catheter specifically indicated for VT, a category with no direct competitor. That is not a market share play. It is a category creation play.
ElectrophysiologyClinical DataPFA
Why This Matters for Builders
Medtronic looked at the AF ablation market—where Farapulse, PulseSelect, Varipulse, and Volt are all fighting for the same indication—and chose to build for a different patient population entirely. VT ablation in structural heart disease is a smaller market than AF, but it has almost no competition, massive unmet clinical need, and the FDA breakthrough pathway accelerates the regulatory timeline. When four well-capitalized companies are racing for the same clearance, the highest-margin move is often not to run the same race faster. It is to run a different race where you are the only entrant. Sphere-9 is a textbook example of that strategy.
Abbott presented results from the FlexPulse IDE trial at HRS 2026, showing its TactiFlex Duo catheter achieved an 87% freedom-from-arrhythmia rate at six months in patients with paroxysmal atrial fibrillation. TactiFlex Duo is the first catheter that combines both pulsed-field ablation and radiofrequency ablation in a single device, allowing the operator to switch between energy modalities during the same procedure without exchanging catheters. The trial met its primary safety and efficacy endpoints. Abbott is preparing regulatory submissions for both the U.S. and European markets. (Source: Abbott, HRS 2026, May 12–14)
The dual-energy architecture addresses a real procedural limitation. PFA is effective for pulmonary vein isolation but certain atrial substrates—particularly posterior wall tissue near the esophagus—may respond better to RF energy. Current practice requires switching catheters mid-procedure, adding time, cost, and complexity. TactiFlex Duo eliminates that trade-off: operators select the energy modality in real time based on the tissue they are treating. The 87% arrhythmia-free rate compares favorably with published single-modality PFA results, though head-to-head data does not yet exist.
Why It Matters: Abbott is not arguing that PFA is better than RF or that RF is better than PFA. It is making the argument irrelevant by offering both in the same catheter. In a market where clinical consensus on the optimal ablation modality has not yet solidified, platform flexibility beats ideological purity. The operator does not need to predict which energy source is best before the procedure starts—they decide in real time, per-lesion. That eliminates the switching cost that locks hospitals into a single modality.
ElectrophysiologyClinical DataAblation
Know someone in electrophysiology or MedTech who should be reading this? Forward this issue to a colleague. Five minutes of signal, no noise.
Boston Scientific presented data from the ELEVATE-PF trial at HRS 2026, showing its next-generation FARAFLEX pulsed-field ablation system achieved 95.5% pulmonary vein isolation durability at a two-month invasive remapping study in patients with paroxysmal atrial fibrillation. FARAFLEX is the successor to Farapulse—the first PFA system cleared in the U.S.—and incorporates a redesigned catheter with improved tissue contact and energy delivery. The ELEVATE-PF trial enrolled patients across multiple U.S. and European centers. BSX is targeting a regulatory submission in 2026. (Source: Boston Scientific, HRS 2026, May 12–14)
The 95.5% PVI durability at two months is a strong early signal, but the electrophysiology community evaluates ablation catheters primarily on 12-month freedom-from-arrhythmia endpoints. Two-month durability is a necessary condition—if pulmonary veins reconnect early, long-term efficacy collapses—but it is not sufficient to prove durable clinical outcomes. BSX needs the longer-term follow-up to convert this data into the clinical guidelines and hospital contract wins that drive commercial adoption.
Why It Matters: BSX built the PFA category with Farapulse and then watched Medtronic, J&J, and Abbott take meaningful share over the past two quarters. FARAFLEX is the counter-move: a next-generation system designed to recapture the clinical edge that Farapulse lost as the market matured. The 95.5% PVI durability number is good enough to hold the narrative at HRS. Whether it is good enough to reverse the market share trend depends on the 12-month data and the speed of regulatory clearance relative to the competition.
ElectrophysiologyPFAClinical Data
Market Movers
MedTech Stocks, Week of May 11–14, 2026
Ticker
Company
Price
Wk Change
ISRG
Intuitive Surgical
$460.30
▲ 0.7%
SYK
Stryker
$297.80
▲ 0.9%
BDX
BD (Becton Dickinson)
$148.60
▲ 0.9%
JNJ
Johnson & Johnson
$223.90
▲ 0.7%
ABT ★
Abbott
$91.00
▲ 3.5%
EW
Edwards Lifesciences
$85.20
▲ 0.7%
ZBH
Zimmer Biomet
$83.80
▲ 0.8%
MDT
Medtronic
$76.40
▲ 2.0%
GEHC
GE HealthCare
$63.10
▲ 1.1%
BSX
Boston Scientific
$56.20
▲ 2.6%
★ Biggest Mover: ABT rose 3.5% on the week as Abbott’s TactiFlex Duo dual-energy catheter data at HRS 2026 impressed the market. MDT gained 2.0% on Sphere-9 VT data. BSX bounced 2.6% on FARAFLEX PVI durability results after weeks of post-guidance-cut selling. All three EP players rallied on HRS data, reflecting investor appetite for ablation catheter clinical evidence. Sorted by stock price, highest to lowest. Prices reflect approximate close, week of May 11–14, 2026. For illustrative purposes only.
Deep Dive
The PFA Arms Race: Three Catheters, Three Strategies, One Conference
HRS 2026 was the first major cardiology meeting where three different companies presented pivotal or late-stage ablation catheter data in the same 72-hour window. That is not a coincidence. It is the structural signal that the PFA market has entered its competitive maturation phase—the point where the clinical question shifts from “does this technology work?” to “whose implementation wins?”
Medtronic is playing a different game. While Abbott and BSX compete head-to-head in AF ablation, Medtronic’s Sphere-9 targets ventricular tachycardia—a harder clinical problem with fewer solutions and no direct PFA competitor. The 65.5% VT-free rate at six months may look modest compared to 87% or 95.5% in AF, but VT ablation in structural heart disease starts from a much lower clinical baseline. Medtronic is not trying to win the AF market. It is trying to own the VT market before anyone else arrives.
Abbott is betting that the modality debate is a feature, not a bug. TactiFlex Duo’s dual-energy architecture makes the PFA-versus-RF argument irrelevant for the operator. In a market where clinical consensus has not yet solidified on the optimal energy source for every atrial substrate, giving the operator both options in real time is a structural advantage. The 87% arrhythmia-free rate is competitive, but the real moat is procedural flexibility—hospitals that adopt TactiFlex Duo reduce their catheter inventory and eliminate the mid-procedure swap that current workflows require.
Boston Scientific is defending the franchise it built. BSX pioneered PFA with Farapulse and then watched competitors erode its market share for two consecutive quarters. FARAFLEX is the response: a redesigned system optimized for the clinical benchmarks the EP community is now using to evaluate second-generation PFA. The 95.5% PVI durability at two months is strong, but BSX needs 12-month data to reclaim the narrative and reverse the guidance cut that took 10% off its stock price in April.
The PFA market is following the same maturation curve as surgical robotics: a first-mover defines the category, the clinical community establishes the benchmark, and then well-capitalized competitors enter with architecturally differentiated products. The difference this time is speed. Surgical robotics took two decades to reach four-company competition. PFA reached it in under three years. The window to lock in hospital contracts, train physicians, and build reimbursement infrastructure is compressing. Whoever has the strongest 12-month data and the fastest regulatory pathway by late 2026 sets the terms for the next five years of EP market structure.
The Builder’s Take
Abbott’s Dual-Energy Catheter Is the Smartest Product Strategy at HRS.
When the market has not yet reached consensus on the optimal approach, the winning product strategy is not to bet on one side of the debate. It is to make the debate irrelevant. Abbott’s TactiFlex Duo does exactly this: it lets the physician choose PFA or RF per-lesion, in real time, without swapping catheters. That is not a clinical innovation. It is a procurement and workflow innovation disguised as a clinical one.
Hospitals that adopt TactiFlex Duo reduce their catheter inventory from two devices to one. Operators who are uncertain whether PFA or RF is better for a specific substrate no longer need to decide before the procedure starts. The switching cost of choosing Abbott drops to zero, while the switching cost of leaving Abbott rises with every procedure performed on the platform. In markets where clinical consensus is still forming, platform flexibility is the only durable moat.
⏳ That’s your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact — The Birth of Catheter Ablation
The first catheter ablation was performed in 1981 using direct-current shocks. RF replaced it in the late 1980s, then came PFA.
Trivia
MedTech Trivia
What is the approximate duration of each electrical pulse delivered during a PFA procedure, and what property of cardiac cells makes them preferentially susceptible to electroporation compared to surrounding structures?
Your answer:
Think you know? 👇 Scroll to the footer for the answer.
👇 Answer at the bottom ↓
MedTech Crossword
✎ MedTech Crossword — Issue #22 Edition — Click a white cell to enter your answer
Click any white cell and type your answer. Arrows move between cells.
3A Prefix meaning “heart” in ___vascular or ___logy (6)
5A ___ Scientific, FARAFLEX PFA maker (6)
7A Type of fibrillation targeted by PFA catheters (6)
Down
2D Cardiac imaging modality: ___cardiogram (4)
4D TactiFlex Duo maker with 87% arrhythmia-free data (6)
Across
1A: SPHERE
3A: CARDIO
5A: BOSTON
7A: ATRIAL
Down
2D: ECHO
4D: ABBOTT
If you’re building, hiring, or investing in MedTech, reply and tell me what you’re seeing. I read every response.
Sponsor
Sponsor This Newsletter
Interested in sponsoring The MedTech Minute?
The MedTech Minute is a focused, twice-weekly newsletter for the medical device industry. Get in front of the founders, engineers, investors, and clinicians who read it. Email us at themedtechminutenewsletter@gmail.com to discuss placement options.
This content is for informational purposes only and does not constitute financial, investment, or medical advice. Always consult qualified professionals before making decisions based on information in this newsletter.
That’s your MedTech Minute.
Medtronic aimed at VT. Abbott offered both energies. BSX defended the franchise. Three catheters walked into HRS with data—the EP market walked out with a new competitive structure. Prescribed reading: complete.
